Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer

NCT04332744 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04332744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04332744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
September 2, 2020
Completion date
May 6, 2025
Enrollment
54 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer